The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A Phase II trial evaluating CD19/CD22 bispecific CAR T-cell therapy in R/R DLBCL
In this video, Liang Wang, PhD, Beijing Tongren Hospital, Beijing, China, discusses the results of a Phase II trial (NCT06081478) investigating CD19/CD22 bispecific CAR T-cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated impressive efficacy and a favourable safety profile in this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
Transcript
We conducted a prospective clinical trial using a novel CAR-T. We targeted both CD19 and CD22 to treat the relapsed, refractory, diffuse large B-cell lymphoma, and this is the prospective trial. What we want to find is the safety profile and the efficacy of this novel CAR-T. We know all approved CAR-T products were targeting CD19 single target and from the long-term follow-up data of the ZUMA-1 study only one third of patients were cured and the remaining patients relapsed again or did not even respond...
We conducted a prospective clinical trial using a novel CAR-T. We targeted both CD19 and CD22 to treat the relapsed, refractory, diffuse large B-cell lymphoma, and this is the prospective trial. What we want to find is the safety profile and the efficacy of this novel CAR-T. We know all approved CAR-T products were targeting CD19 single target and from the long-term follow-up data of the ZUMA-1 study only one third of patients were cured and the remaining patients relapsed again or did not even respond. And the mechanisms were very complicated, maybe due to the CD19 antigen loss or the exhaustion of CAR-T cells or the immunosuppressive microenvironment. So we conducted this clinical trial to further improve the efficacy and prognosis. Till February this year, 31 patients were enrolled and were able to evaluate the response. We can see the best overall survival, best overall response rate were 100% and the complete remission rate was 67.7%. And the median follow-up time was 8.1 months, but the PFS and the OS were not reached. And the estimates of 12 months PFS were more than 60%. The data is much higher than the ZUMA-1 study. So we have shown the efficacy of this novel CAR-T therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
